Navigation Links
Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
Date:3/7/2011

their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

As we expanded our number of Tumorgraft models, we began to offer leading pharmaceutical and biotechnology companies the benefits of our Tumorgraft Technology Platform for their pharmaceutical development programs.  We provide Translational Oncology Solutions, or TOS, (previously referred to as Preclinical eValuation services) that we believe are predictive of clinical outcomes and that might provide for a faster and less expensive path to drug approval.  These services utilize Tumorgrafts to evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents.  TOS also includes biomarker discovery and the identification of novel drug combinations.  We began deriving revenues from our TOS services in fiscal 2009 and completed our first full year of business in fiscal 2010.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsbiotechnology.com.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Co
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Additions to its Management Team
2. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
3. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
4. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
7. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
8. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
11. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Due to a misstatement posted by the Family Resource ... Center, LLC ( ASCTC ) was reported as an entity ... benefit ALS patients. Because of ASCTC's exclusive focus on ... therapeutic applications, FRC listed ASCTC as one of several alternatives ... not to support research that requires the death of human ...
(Date:8/28/2014)... SPIE Fellow Glenn Boreman, Professor and ... and Director of the Center for Optoelectronics and Optical ... and co-founder and Chairman of the Board of Plasmonics, ... Vice President of SPIE, the international society for optics ... recent election results at the Annual General Meeting of ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... -- Theoretical work done at the Department of Energy,s ... understanding an unexpected magnetism between two dissimilar materials. ... special significance for the design of future electronic devices ... of ORNL,s Materials Science and Technology Division. The work ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today ... September 30, 2010 after the market closes on Wednesday, November ... Chief Executive Officer, Kent Griffin, President, and Greg N. Lubushkin, ... 9:00 a.m. Pacific Time on Thursday, November 4, 2010 to ...
... England, Oct. 18 A 67-year-old female patient with ... tumor was small and it rode up and down ... doctors saw on their therapy system,s imaging equipment was ... Trust was able to utilize its Symmetry™ motion ...
Cached Biology Technology:ORNL theorist part of team that discovers unexpected magnetism 2BioMed Realty Trust to Report 2010 Third Quarter Results 2Clinicians Use Advanced Radiotherapy Imaging Techniques from Elekta to More Accurately Visualize Moving Tumors in Patients with Lung Cancer 2Clinicians Use Advanced Radiotherapy Imaging Techniques from Elekta to More Accurately Visualize Moving Tumors in Patients with Lung Cancer 3
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... that an expansion of marine protected areas is needed ... According to investigators from the Wildlife Conservation Society ... focused on saving the largest numbers of species, often ... and difficult-to-replace ecological functions. , Many vital ... species that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... , , , , ... Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of ... entry into a Loan and Security Agreement with Terry M. Giles, ... In connection with, and as required by the Loan, on ...
... , , , , ... Reportlinker.com announces that a new market research report is available in ... Signature Verification Market , , ... worldwide markets for Dynamic Signature Verification in US$ Thousands. The market ...
... , WALL, N.J., Sept. 14 / PRNewswire-FirstCall / ... a leader in finger-based biometric identification and wireless public safety solutions, ... Advisor and Consultant to the company. Tom will play a major ... the government and commercial markets. , , (Logo: ...
Cached Biology News:Pacific Biometrics Completes $4 Million Debt Financing 2Pacific Biometrics Completes $4 Million Debt Financing 3Pacific Biometrics Completes $4 Million Debt Financing 4Pacific Biometrics Completes $4 Million Debt Financing 5Reportlinker Adds World Dynamic Signature Verification Market Report 2Reportlinker Adds World Dynamic Signature Verification Market Report 3Reportlinker Adds World Dynamic Signature Verification Market Report 4Reportlinker Adds World Dynamic Signature Verification Market Report 5Reportlinker Adds World Dynamic Signature Verification Market Report 6Reportlinker Adds World Dynamic Signature Verification Market Report 7Reportlinker Adds World Dynamic Signature Verification Market Report 8Reportlinker Adds World Dynamic Signature Verification Market Report 9BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 2BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 3BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant 4
... was developed using a protein engineering approach that ... pocket of wild-type DNase I. These changes markedly ... The result is a versatile enzyme that has ... ability to maintain at least 50% of peak ...
Request Info...
MAb to Mouse MHC Class I H-2Kd...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: